Inspiration Healthcare Group plc

DB:LXD1 Stock Report

Market Cap: €16.9m

Inspiration Healthcare Group Valuation

Is LXD1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LXD1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: LXD1 (€0.19) is trading below our estimate of fair value (€1.26)

Significantly Below Fair Value: LXD1 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LXD1?

Key metric: As LXD1 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for LXD1. This is calculated by dividing LXD1's market cap by their current revenue.
What is LXD1's PS Ratio?
PS Ratio0.4x
SalesUK£34.30m
Market CapUK£14.12m

Price to Sales Ratio vs Peers

How does LXD1's PS Ratio compare to its peers?

The above table shows the PS ratio for LXD1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.2x
GME Geratherm Medical
0.9x1.9%€16.5m
AAQ1 aap Implantate
1.9xn/a€22.4m
AUG Audientes
12.6xn/a€6.9m
NN6 NanoRepro
5.3xn/a€18.9m
LXD1 Inspiration Healthcare Group
0.4x13.6%€14.1m

Price-To-Sales vs Peers: LXD1 is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (2.7x).

Price to Sales Ratio vs Industry

How does LXD1's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.2x4.2%US$836.09m
PHH2 Paul Hartmann
0.3xn/aUS$779.09m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
LXD1 0.4xIndustry Avg. 3.7xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: LXD1 is good value based on its Price-To-Sales Ratio (0.4x) compared to the European Medical Equipment industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is LXD1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LXD1 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.4x
Fair PS Ratio0.6x

Price-To-Sales vs Fair Ratio: LXD1 is good value based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

LNA Santé

€244.9m

Engages in the management and operation of health establishments.

2N3

€23.30

7D

-5.3%

1Y

19.1%

Shandong Weigao Group Medical Polymer

HK$19.8b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.51

7D

-10.5%

1Y

-38.6%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%